Intensity Therapeutics Inc INTS
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2023-06-30 |
| Shares Out. | 2,700,000 |
| Website | intensitytherapeutics.com ↗ |
| Phone | 12032217381 |
| Employees | 7 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$3.0M |
| Free Cash Flow | -$9.0M |
| Total Assets | $11.5M |
| Total Liabilities | $2.3M |
| Equity | $9.2M |
About Intensity Therapeutics Inc
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Intensity Therapeutics Inc is a publicly traded company under the ticker symbol INTS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-09-01)